Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy.

This prospective, double-blind trial assessed whether the addition of a glycopeptide would be able to reduce the time to defervescence in neutropenic patients with cancer who had persistent fever 48-60 h after the initiation of empirical piperacillin-tazobactam monotherapy. Of 763 eligible patients, 165 with persistent fever were randomized to receive piperacillin-tazobactam therapy plus either vancomycin therapy or placebo. Defervescence was observed in 82 (95%) of 86 patients in the vancomycin group and in 73 (92%) of 79 patients in the placebo group (P=.52). The distributions of the time to defervescence were not statistically significant between the 2 groups (estimated hazard ratio, 1.03; 95% confidence interval, 0.75-1.43; P=.75). The number of additional episodes of gram-positive bacteremia and the percentage of patients for whom amphotericin B was empirically added to their therapy regimen were also similar in both groups. This study failed to demonstrate that the empirical addition of vancomycin therapy to the treatment regimen is of benefit to persistently febrile neutropenic patients with cancer.

[1]  T. Calandra,et al.  Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer , 2002 .

[2]  Robert E. Johnson,et al.  From the Centers for Disease Control. Staphylococcus aureus resistant to vancomycin--United States, 2002. , 2002, JAMA.

[3]  G. Moran,et al.  Staphylococcus aureus resistant to vancomycin--United States, 2002. , 2002, MMWR. Morbidity and mortality weekly report.

[4]  F. Mandelli,et al.  A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  R. Stephan,et al.  Prevalence of colonisation and resistance patterns of vancomycin-resistant enterococci in healthy, non-hospitalised persons in Switzerland. , 2001, Swiss medical weekly.

[6]  R. Ramphal,et al.  Randomized, double-blind, multicenter trial comparing clinafloxacin with imipenem as empirical monotherapy for febrile granulocytopenic patients. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  M. Laseur,et al.  A prospective, randomized, double-blinded, placebo-controlled trial of empirical teicoplanin in febrile neutropenia with persistent fever after imipenem monotherapy. , 2000, The Journal of antimicrobial chemotherapy.

[8]  B. Murray,et al.  Vancomycin-resistant enterococcal infections. , 2000, The New England journal of medicine.

[9]  H. Tate,et al.  A meta-analysis of clinical studies of imipenem-cilastatin for empirically treating febrile neutropenic patients. , 1996, The Journal of antimicrobial chemotherapy.

[10]  M. Paesmans,et al.  Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer , 1995, Antimicrobial agents and chemotherapy.

[11]  S. Steinberg,et al.  Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Elaine Larson,et al.  Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). , 1995, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[13]  R. Feld,et al.  Ceftazidime Compared with Piperacillin and Tobramycin for the Empiric Treatment of Fever in Neutropenic Patients with Cancer: A Multicenter Randomized Trial , 1994, Annals of Internal Medicine.

[14]  K. Singh,et al.  Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  H D Isenberg,et al.  Vancomycin-Resistant Enterococcus faecium in Hospitalized Children , 1992, Infection Control & Hospital Epidemiology.

[16]  B. Kramer,et al.  Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study , 1992, Antimicrobial Agents and Chemotherapy.

[17]  Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada-Clinical Trials Group. , 1991, The Journal of infectious diseases.

[18]  S. Steinberg,et al.  Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. , 1988, Annals of internal medicine.